Heart Failure with Reduced Ejection Fraction (HFrEF) Management

Core Medication Classes for HFrEF

The American College of Cardiology recommends initiating and optimizing four medication classes: SGLT2 inhibitors, ARNi/ACEi/ARB, beta-blockers, and mineralocorticoid receptor antagonists (MRAs) to reduce mortality and hospitalizations in patients with HFrEF 1, 2, 3
SGLT2 inhibitors (empagliflozin 10mg daily or dapagliflozin 10mg daily) should be started early to reduce heart failure hospitalizations and cardiovascular mortality, with minimal effect on blood pressure 1, 2, 4
Mineralocorticoid Receptor Antagonists (MRAs) (spironolactone 12.5-25mg daily or eplerenone 25mg daily) are indicated for patients with LVEF ≤35% and NYHA class II-IV symptoms 2, 5
Beta-blockers (carvedilol, metoprolol succinate, or bisoprolol) should be initiated at low doses and titrated to target doses to reduce mortality and hospitalizations 5, 6
ARNi (sacubitril/valsartan) is recommended as a replacement for ACEi/ARB in patients who remain symptomatic despite optimal treatment with other therapies, starting with low dose (24/26mg-49/51mg twice daily) and titrating to 97/103mg twice daily 5, 6

Special Populations and Considerations

The American College of Cardiology recommends that patients with previous HFrEF who improve their LVEF to >40% (termed HFimpEF) should continue their HFrEF treatment regimen 3, 7
Ivabradine (starting at 2.5-5mg twice daily) should be considered for patients in sinus rhythm with heart rate ≥70 bpm despite maximally tolerated beta-blocker therapy 5
Hydralazine and isosorbide dinitrate combination provides additional benefit in self-identified African American patients with NYHA class III-IV symptoms despite optimal therapy 5, 7

Device Therapies

Implantable cardioverter-defibrillator (ICD) is recommended for primary prevention in patients with LVEF ≤35% despite ≥3 months of optimal medical therapy, with expected survival >1 year 6
Cardiac resynchronization therapy (CRT) is indicated for patients with LVEF ≤35%, sinus rhythm, left bundle branch block with QRS duration ≥150 ms, and NYHA class II-IV symptoms despite optimal therapy 7

Medication Target Doses

The American College of Cardiology recommends target doses for beta-blockers: Bisoprolol 10mg once daily, Carvedilol 25-50mg twice daily, Metoprolol succinate 200mg daily 5
Target doses for ARNi: Sacubitril/valsartan 97/103mg twice daily 5
Target doses for MRAs: Eplerenone 50mg daily, Spironolactone 25-50mg daily 5
Target doses for SGLT2 inhibitors: Dapagliflozin 10mg daily, Empagliflozin 10mg daily 5

Combining Eplerenone with ARNI, Beta Blocker, SGLT2 Inhibitor, and Diuretic in Resistant HFrEF

Rationale for Combination Therapy

Eplerenone is considered a preferred agent in resistant hypertension and can be used at doses of 50-100 mg daily (once or twice daily dosing) 8

Safety Considerations

The American College of Cardiology recommends close monitoring of renal function, potassium levels, and blood pressure is essential when combining these medications 9
The risk of hyperkalemia increases when MRAs like eplerenone are added to ARNI therapy, requiring regular laboratory monitoring 10
The American Heart Association suggests that routine combined use of an ACEI, ARB, and aldosterone antagonist is not recommended, but an ARNI can be safely combined with an MRA 11
Loop diuretic doses may need adjustment when initiating or titrating these medications to prevent excessive diuresis, as recommended by the American College of Cardiology 9

Monitoring Recommendations

The European Society of Cardiology recommends checking renal function and electrolytes before initiating eplerenone 10
Monitor electrolytes (especially potassium) and renal function 2-3 days after initiation, then monthly for 3 months, and every 3 months thereafter, as suggested by the European Society of Cardiology 10
Avoid eplerenone use in patients with significant renal dysfunction (eGFR <30 mL/min/1.73m²), according to the American College of Cardiology 12

Dosing Considerations

Eplerenone often requires twice-daily dosing for adequate blood pressure lowering in resistant cases, as reported in Hypertension 8
Target dose for eplerenone is 50 mg daily, though doses up to 100 mg daily may be used with close monitoring, as recommended by the American Heart Association 13
Consider reducing loop diuretic doses when adding eplerenone to prevent excessive diuresis, especially in patients already on SGLT2 inhibitors, as suggested by the American College of Cardiology 9

Special Precautions

Avoid the combination in patients with potassium >5.0 mmol/L or eGFR <30 mL/min/1.73m², as recommended by the European Society of Cardiology 10
Consider temporary discontinuation of eplerenone during acute illness that may affect renal function or potassium levels, as suggested by the European Society of Cardiology 10

Initiation and Up‑titration of Guideline‑Directed Medical Therapy in Clinically Stable HFrEF

Initial Assessment Before Starting GDMT

Verify that left‑ventricular ejection fraction is ≤ 40 % using echocardiography or an equivalent imaging modality. 14
Obtain baseline natriuretic peptide (BNP or NT‑proBNP) levels to provide prognostic information and a reference for future therapy adjustments. 14
Record baseline blood pressure and heart rate to guide the initial dosing of all four medication classes. [15][16]
Assess volume status (e.g., signs of congestion) to determine the need for loop diuretics before GDMT initiation. 15

Simultaneous Initiation of the Four Foundational Pillars (Weeks 1‑2)

SGLT2 inhibitor – Start dapagliflozin 10 mg daily or empagliflozin 10 mg daily at full dose immediately; these agents lower cardiovascular mortality and HF hospitalizations independent of diabetes status and have minimal blood‑pressure effects. 17
Mineralocorticoid‑receptor antagonist (MRA) – Begin spironolactone 12.5‑25 mg daily (or eplerenone 25 mg daily) in patients with LVEF ≤ 35 % and NYHA class II‑IV symptoms; MRAs confer mortality benefit with little impact on blood pressure. 17
Beta‑blocker – Initiate carvedilol 3.125 mg twice daily, metoprolol succinate 12.5‑25 mg daily, or bisoprolol 1.25 mg daily, provided resting heart rate > 50 bpm and no significant bradycardia; beta‑blockers reduce mortality and sudden cardiac death across HFrEF. 17
ARNI (preferred) or ACEi/ARB – Start sacubitril/valsartan 24/26 mg or 49/51 mg twice daily (preferred for superior mortality reduction); if ARNI is not feasible, begin enalapril 2.5‑5 mg twice daily or lisinopril 2.5‑5 mg daily. [17][18]

Up‑titration Strategy (Weeks 2‑12)

Increase one medication at a time every 1‑2 weeks, selecting the class most likely to be tolerated based on hemodynamics. [15][16]
If heart rate > 70 bpm, prioritize beta‑blocker up‑titration to target doses (carvedilol 25‑50 mg bid, metoprolol succinate 200 mg daily, bisoprolol 10 mg daily). 18
If systolic blood pressure > 100 mmHg, up‑titrate ARNI/ACEi/ARB toward the target sacubitril/valsartan dose of 97/103 mg twice daily. 18
If serum potassium < 4.5 mmol/L and renal function is stable, up‑titrate MRA toward spironolactone 25‑50 mg daily (or eplerenone 50 mg daily). 18
SGLT2 inhibitor remains at full dose throughout the titration period.

Before each dose increase, re‑measure blood pressure and heart rate; after each MRA or ARNI/ACEi increase, re‑check potassium and creatinine 1‑2 weeks later. [15][16]

Management of Common Hemodynamic Barriers

Asymptomatic low systolic BP (90‑100 mmHg) – Continue all four GDMT agents at current doses; low BP alone does not predict adverse outcomes. Educate patients that transient orthostatic dizziness is expected and does not require dose reduction. [15][16]
Symptomatic hypotension (SBP < 80 mmHg or severe symptoms) – Temporarily hold or reduce the most recently up‑titrated drug, preferentially non‑GDMT antihypertensives first; consider splitting ARNI dosing or switching to a lower‑dose ACEi if needed. Never discontinue SGLT2 inhibitor or MRA for low BP alone. [15][16]
Bradycardia (HR < 50 bpm) – Reduce beta‑blocker dose by ~50 %; if the patient remains in sinus rhythm with HR ≥ 70 bpm, add ivabradine 2.5‑5 mg twice daily as adjunct. Confirm absence of AV block with ECG before continuing beta‑blocker and consider pacemaker evaluation if severe bradycardia persists. [18][19]

Special Populations

African‑American patients with NYHA class III‑IV – Add hydralazine 37.5 mg three times daily plus isosorbide dinitrate 20 mg three times daily; up‑titrate to hydralazine 75 mg TID and isosorbide dinitrate 40 mg TID for additional mortality benefit. [17][18]
Atrial fibrillation with rapid ventricular response – Aggressively up‑titrate beta‑blocker for rate control; if insufficient, add digoxin 0.125 mg daily (avoid amiodarone for rate control). 18

Long‑Term Maintenance

Continue GDMT indefinitely, even if LVEF improves above 40 % (HFimpEF), because withdrawal is associated with relapse of ventricular dysfunction and clinical HF. [17][14]
Re‑assess LVEF every 6‑12 months with echocardiography to monitor trajectory and determine eligibility for device therapy (e.g., ICD if LVEF remains ≤ 35 % after ≥ 3 months of optimal GDMT).
Laboratory monitoring – Check serum potassium and creatinine every 3 months once stable on target doses.
Natriuretic peptide measurement can be used to guide further therapy adjustments when clinical status is uncertain. 14